A lawsuit filed in New Jersey state court claims that Fosamax caused multiple stress fractures and suppressed bone regeneration in the legs of a woman who took Fosamax for 10 years. More than 400 people already have sued manufacturer Merck alleging that Fosamax causes a bone-decaying condition known as osteonecrosis of the jaw. Osteonecrosis of the jaw is a serious condition in which bone tissue dies, resulting in the loss or destruction of the jawbone. Symptoms may include pain, swelling or infection of the gums and jaw, gums that don’t heal, loose teeth and numbness of the jaw.
The allegations and concerns that the drugmaker’s osteoporisis med may cause problems in the jaw – known as osteonecrosis – are well known at this point. Now this new issue has emerged. Merck has stated that this lawsuit represents an isolated incident, but it is not unreasonable to believe that if Fosamax can cause problem in the jaw bone, it could cause problems in other bones as well.
Fosamax generated sales of nearly $3 billion in 2007 for Merck.
Shipman & Wright, L.L.P. is representing women who took Fosamax and developed bone-wasting conditions.